Skip to main content

Bronchospasm

3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
1
2
Fluticasone propionate/salmeterolPhase 4
Fluticasone propionate/salmeterolPhase 4
GSK615915APhase 1
GSK
GSKLONDON, United Kingdom
2 programs
Fluticasone propionate/salmeterolPHASE_41 trial
Fluticasone propionate/salmeterolPHASE_41 trial
Active Trials
NCT00118690Completed227Est. Dec 2005
NCT00118716Completed248Est. Apr 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKFluticasone propionate/salmeterol
GSKFluticasone propionate/salmeterol

Clinical Trials (2)

Total enrollment: 475 patients across 2 trials

NCT00118716GSKFluticasone propionate/salmeterol

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Start: Dec 2003Est. completion: Apr 2006248 patients
Phase 4Completed
NCT00118690GSKFluticasone propionate/salmeterol

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Start: Dec 2003Est. completion: Dec 2005227 patients
Phase 4Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.